Develops cannabinoid-based therapies to address unmet medical needs in oncology, neurology, and supportive care, focusing on enhancing patient quality of life.
Enveric Biosciences, Inc. is a pioneering biotechnology company focused on developing small-molecule therapeutics aimed at treating anxiety, depression, and addiction disorders. Leveraging its innovative discovery and development platform, The Psybrary, the company has assembled a portfolio of novel chemical entities tailored to address specific mental health indications.
At the forefront of its research is the EVM201 series, a lead program featuring next-generation synthetic psilocybin analogues designed as prodrugs of the active metabolite psilocin. Enveric Biosciences is also advancing its third-generation therapeutics, the EVM301 Series, targeting a range of central nervous system disorders.
Headquartered in Naples, Florida, with additional offices in Cambridge, Massachusetts, and Calgary, Canada, Enveric Biosciences remains committed to advancing the frontier of mental health treatment. The company's dedication to innovation and therapeutic advancement underscores its mission to enhance the well-being of patients worldwide through groundbreaking pharmaceutical solutions.